The company said it is firing Moncef Slaoui from his position as board chair at Galvani Bioelectronics, effective immediately, after its investigation substantiated a complaint about his conduct toward an employee “several years ago” when Slaoui worked for the drugmaker.
GlaxoSmithKline is a majority shareholder of Galvani Bioelectronics.
Slaoui served as chief science adviser to Operation Warp Speed, which was launched under the Trump administration to develop vaccines and treatments for COVID-19.
Slaoui could not be reached Wednesday for comment. Emails to the recently launched Centessa Pharmaceuticals, where Slaoui is listed as chief scientific officer, and Medicxi, where he is listed as a partner, were not immediately returned.
GlaxoSmithKline said its investigation began after it received a letter in February outlining the allegations of “sexual harassment and inappropriate conduct." It said that Slaoui's conduct was “unacceptable" and an “abuse of his leadership position." It did not provide further details.
Slaoui spent nearly 30 years at GlaxoSmithKline, holding roles including chair of pharmaceutical research and development, chair of global research and development and board member, according to Centessa's website.